Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Proteon Therapeutics Inc.

Headquarters: Waltham, MA, United States of America
Website: N/A
Year Founded: 2001
Status: Reverse-merged

BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy
BioCentury | May 9, 2019
Company News

Management tracks: Akebia, Sangamo, Bicycle

BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks up in 1Q19 after 2018 losses
BioCentury | Apr 5, 2019
Clinical News

Proteon's vonapanitase misses another Phase III

BioCentury | May 12, 2017
Clinical News

Proteon ups Phase III PATENCY-2 enrollment

BioCentury | Mar 17, 2017
Clinical News

Vonapanitase: Ph III PATENCY-2 amended

BioCentury | Dec 16, 2016
Clinical News

Vonapanitase: Ph III PATENCY-1 data

BioCentury | Dec 14, 2016
Clinical News

Proteon crumbles after Phase III patency miss

Items per page:
1 - 10 of 54